Pharmacokinetics and pharmacodynamics of once- and twice-daily multiple-doses of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 6, 2015, Pages 438-446

  Devineni, Damayanthi ^a   Polidori, David ^b   Curtin, Christopher R ^a   Murphy, Joseph ^a   Wang, Shean Sheng ^a   Stieltjes, Hans ^b   Wajs, Ewa ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Canagliflozin; Pharmacodynamics; Pharmacokinetics; Sodium glucose co transporter 2 inhibitor; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; GLUCOSE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; EXPOSURE RESPONSE RELATIONSHIP; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HUMAN; HYPOGLYCEMIA; INFECTION; INFESTATION; MALE; MAXIMUM PLASMA CONCENTRATION; NEUROLOGIC DISEASE; NORMAL HUMAN; OPEN STUDY; PHARMACOLOGICAL PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; POLLAKISURIA; SKIN DISEASE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; URINE ODOR; VULVOVAGINAL DISCOMFORT; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BLOOD; DRUG ADMINISTRATION; DRUG EFFECTS; DRUG MONITORING; HALF LIFE TIME; METABOLISM; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BLOOD GLUCOSE; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; GLUCOSIDES; HALF-LIFE; HEALTHY VOLUNTEERS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MODELS, BIOLOGICAL; RISK ASSESSMENT; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES; YOUNG ADULT;

EID: 84936751014     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202324     Document Type: Article

References (22)

1. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009; 75: 1272-1277. CrossRef PubMed
2. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest. 1951; 30: 125-129. CrossRef PubMed
3. Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl. 2007; 72: S27-S35. CrossRef PubMed
4. Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010; 95: 34-42. CrossRef PubMed
5. Polidori D, Sha S, Ghosh A, Plum-Mörschel L, Heise T, Rothenberg P. Validation of a novel method for determining the renal threshold for glucose excretion in untreated and canagliflozintreated subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013; 98: E867-E871. CrossRef PubMed
6. Rave K, Nosek L, Posner J, Heise T, Roggen K, van Hoogdalem EJ. Renal glucose excretion as a function of blood glucose concentration in subjects with type 2 diabetes--results of a hyperglycaemic glucose clamp study. Nephrol Dial Transplant. 2006; 21: 2166-2171. CrossRef PubMed
7. Canagliflozin (Invokana™) Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2013. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/204042s000lbl.pdf. Accessed on March 5, 2014.; 2013.
8. Canagliflozin (Invokana™) Summary of Product Characteristics. Beerse, Belgium: Janssen-Cilag International NV. 2013. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Pro?d?u?ct-Information/human/002649/WC500156456.pdf. Accessed on March 5, 2014.; 2013.
9. Elkinson S, Scott LJ. Canagliflozin: first global approval. Drugs. 2013; 73: 979-988. CrossRef PubMed
10. Pandey SK, Dass D. Canagliflozin - Beginning of the journey. J Pharm Bioallied Sci. 2014; 6: 132-133. CrossRef PubMed
11. European Commission http://ec.europa.eu/health/documents/community-register/html/newproc.htm#h Last accessed April 15, 2014.
12. Invokamet (canagliflozin and metformin hydrocloride) US FDA Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2014. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/204353s000lbl.pdf. Last accessed September 1, 2014.
13. Devineni D, Vaccaro N, Polidori D, Stieltjes H, Wajs E. Single- and multiple-dose pharmacokinetics and pharmacodynamics of canagliflozin, a selective inhibitor of sodium glucose co-transporter 2, in healthy participants. Int J Clin Pharmacol Ther. 2015; 53: 129-138. CrossRef PubMed
14. Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, Rothenberg PL. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol. 2013; 53: 601-610. CrossRef PubMed
15. Sha S, Devineni D, Ghosh A, Polidori D, Chien S, Wexler D, Shalayda K, Demarest K, Rothenberg P. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2011; 13: 669-672. CrossRef PubMed
16. Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, Morrow L, Spitzer H, Demarest K, Rothenberg P. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS ONE. 2014; 9: e110069. CrossRef PubMed
17. GLUCOPHAGE™ prescribing information, Princeton NJ: Bristol-Myers Squibb. 2009.
18. Glucophage 500 mg and 850 mg film coated tablets. Summary of Product Characteristics (SPC). Merck Serono. 2010.
19. Food and Drug Administration (FDA). Guidance for Industry, Bioanalytical Methods Validation. 2001. http://www.fda.gov/downloads/Drugs/Gui?da?nces/ucm070107.pdf. Accessed 17 February, 2014.
20. Viswanathan C, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, Shah VP, Skelly JP, Swann PG, Weiner R. Workshop/conference report-quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J. 2007; 9: E30-E42. CrossRef
21. Qiu R, Capuano G, Meininger G. Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus. Journal of Clinical & Translational Endocrinology. 2014; 1: 54-60. CrossRef
22. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, Capuano G, Canovatchel W; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012; 35: 1232-1238. CrossRef PubMed